Bartlik B D, Kaplan P, Kaplan H S
Department of Psychiatry, New York Hospital-Cornell University Medical College, USA.
J Sex Marital Ther. 1995 Winter;21(4):264-71. doi: 10.1080/00926239508414646.
Sexual dysfunction secondary to selective serotonin re-uptake inhibitors (SSRIs) is an almost universal, yet pooly understood phenomenon. Not uncommonly, this unpleasant side effect leads to noncompliance. Since SSRIs have been so successful clinically, it is time to find a safe and effective treatment for this side effect. This paper reports on five cases in which low dosages of the psychostimulants, dextroamphetamine and methylphenidate, administered on a p.r.n. basis, reversed the sexually inhibiting side effects of the SSRIs fluxetine, setraline, and paroxetine in patients with and without attention deficit hyperactivity disorder. In addition, the women experienced enhanced levels of arousal, orgasmic sensation and excitement during the resolution phase (afterglow) of the sexual response cycle on psychostimulants, and the men noted firmer erections.
选择性5-羟色胺再摄取抑制剂（SSRI）引发的性功能障碍是一种几乎普遍存在但却鲜为人知的现象。这种令人不适的副作用导致患者停药的情况并不罕见。鉴于SSRI在临床上取得了巨大成功，现在是时候找到一种安全有效的方法来治疗这种副作用了。本文报告了5例病例，这些患者无论是否患有注意力缺陷多动障碍，在按需服用低剂量精神兴奋药右旋苯丙胺和哌醋甲酯后，SSRI类药物氟西汀、舍曲林和帕罗西汀的性抑制副作用均得到逆转。此外，女性在性反应周期的消退期（余韵期）服用精神兴奋药后，性唤起、性高潮感觉和兴奋程度均有所增强，男性则表示勃起更坚挺。
